BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34273443)

  • 21. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
    Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Long Noncoding RNAs Deregulated in Papillary Thyroid Cancer and Correlated with BRAF
    Goedert L; Plaça JR; Fuziwara CS; Machado MCR; Plaça DR; Almeida PP; Sanches TP; Santos JFD; Corveloni AC; Pereira IEG; de Castro MM; Kimura ET; Silva WA; Espreafico EM
    Sci Rep; 2017 May; 7(1):1662. PubMed ID: 28490781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
    Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
    Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
    Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
    Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
    Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
    Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
    Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R
    Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
    Geraldo MV; Nakaya HI; Kimura ET
    Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
    Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Key candidate genes associated with BRAF
    Yu X; Zhong P; Han Y; Huang Q; Wang J; Jia C; Lv Z
    J Cell Physiol; 2019 Dec; 234(12):23369-23378. PubMed ID: 31161615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The lncRNA UNC5B-AS1 promotes proliferation, migration, and invasion in papillary thyroid cancer cell lines.
    Wang Y; Bhandari A; Niu J; Yang F; Xia E; Yao Z; Jin Y; Zheng Z; Lv S; Wang O
    Hum Cell; 2019 Jul; 32(3):334-342. PubMed ID: 30805847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AGK-BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma.
    Cordioli MI; Moraes L; Carvalheira G; Sisdelli L; Alves MT; Delcelo R; Monte O; Longui CA; Cury AN; Cerutti JM
    Cancer Med; 2016 Jul; 5(7):1535-41. PubMed ID: 27037835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
    Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
    Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
    Pang R; Yang S
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.
    Wang Q; Yang H; Wu L; Yao J; Meng X; Jiang H; Xiao C; Wu F
    Thyroid; 2016 Dec; 26(12):1719-1732. PubMed ID: 27758138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
    Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
    J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis.
    Chai YJ; Kim YA; Jee HG; Yi JW; Jang BG; Lee KE; Park YJ; Youn YK
    Surgery; 2014 Dec; 156(6):1559-67; discussion 1567-8. PubMed ID: 25456955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.